A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

Key facts

Sponsor

Prelude Therapeutics

Intervention

PRT12396(drug)

Enrollment

100 enrolled

Eligibility

18 years · All sexes

Timeline

2026 – 2028

Study locations (1)

• START Midwest, LLC, Grand Rapids, Michigan, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06976918
  Registry Platform Myelofibrosis and Anemia
  iOMEDICO AG
• RECRUITINGNCT07203768
  A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
  FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
• RECRUITINGPHASE2NCT06517875
  Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
  GlaxoSmithKline
• RECRUITINGNANCT06734637
  Efficacy and Safety of Peginterferon in ET and PV.
  Zhenya Hong
• RECRUITINGPHASE1NCT06343805
  A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
  Ajax Therapeutics, Inc.
• RECRUITINGPHASE2NCT06541249
  MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
  Icahn School of Medicine at Mount Sinai
• RECRUITINGPHASE2NCT06552429
  Peginterferon α-2b Injection for Hydroxyurea Resistant or Intolerant ET
  Xiamen Amoytop Biotech Co., Ltd.
• RECRUITINGPHASE1, PHASE2NCT06327100
  Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
  M.D. Anderson Cancer Center

See all trials for Essential thrombocythemia →